BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Goette A, Kwong WJ, Ezekowitz MD, Banach M, Hjortshoj SP, Zamoryakhin D, Lip GYH. Edoxaban therapy increases treatment satisfaction and reduces utilization of healthcare resources: an analysis from the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of atrial fibrillation (ENSURE-AF) study. Europace 2018;20:1936-43. [PMID: 29947751 DOI: 10.1093/europace/euy141] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Ahmad S, Wilt H. Stroke Prevention in Atrial Fibrillation and Valvular Heart Disease. Open Cardiovasc Med J 2016;10:110-6. [PMID: 27347228 DOI: 10.2174/1874192401610010110] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
2 Warden BA, MacKay J, Jafari M, Willman A, Stecker EC. Use of Direct Oral Anticoagulants Among Patients Undergoing Cardioversion: The Importance of Timing Before Cardioversion. J Am Heart Assoc 2018;7:e010854. [PMID: 30571504 DOI: 10.1161/JAHA.118.010854] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Proietti M, Vitolo M, Harrison SL, Lane DA, Fauchier L, Marin F, Nabauer M, Potpara TS, Dan GA, Boriani G, Lip GYH; ESC-EHRA EORP-AF Long-Term General Registry Investigators. Real-world applicability and impact of early rhythm control for European patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF Long-Term General Registry. Clin Res Cardiol 2021. [PMID: 34448931 DOI: 10.1007/s00392-021-01914-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Goette A. Uninterrupted NOAC therapy in patients undergoing catheter ablation of atrial fibrillation: "Dual anticoagulant therapy" ready for primetime or systematic overtreatment? Int J Cardiol 2018;270:185-6. [PMID: 29929932 DOI: 10.1016/j.ijcard.2018.06.043] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Jang BM, Lee OS, Shin EJ, Cho EJ, Suh SY, Cho YS, Koo Lee M, Rhie SJ. Factors related to inappropriate edoxaban use. J Clin Pharm Ther 2019;44:760-7. [DOI: 10.1111/jcpt.12999] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Hammwöhner M, Goette A. Ten years of non-vitamin K antagonists oral anticoagulants for stroke prevention in atrial fibrillation: is warfarin obsolete? Eur Heart J Suppl 2020;22:O28-41. [PMID: 33380942 DOI: 10.1093/eurheartj/suaa177] [Reference Citation Analysis]
7 Riva N, Borg Xuereb C, Makris M, Ageno W, Gatt A. Reliability and validity of the Maltese version of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q). Patient Prefer Adherence 2019;13:969-79. [PMID: 31417242 DOI: 10.2147/PPA.S207498] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
8 Katerenchuk V, Duarte GS, Martins E Pereira G, Fernandes RM, Ferreira JJ, Pinto FJ, Costa J, Caldeira D. Satisfaction of Patients with Nonvitamin K Anticoagulants Compared to Vitamin K Antagonists: a Systematic Review and Meta-analysis. Thromb Haemost 2021;121:366-82. [PMID: 33160289 DOI: 10.1055/s-0040-1716752] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Sokol J, Nehaj F, Ivankova J, Mokan M, Lisa L, Zolkova J, Vadelova L, Mokan M, Stasko J. Impact of Edoxaban on Thrombin-Dependent Platelet Aggregation. Clin Appl Thromb Hemost 2020;26:1076029620948585. [PMID: 33054412 DOI: 10.1177/1076029620948585] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, Batushkin V, Campo G, Lysak Z, Vakaliuk I, Milewski K, Laeis P, Reimitz P, Smolnik R, Zierhut W, Goette A. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. The Lancet 2019;394:1335-43. [DOI: 10.1016/s0140-6736(19)31872-0] [Cited by in Crossref: 243] [Cited by in F6Publishing: 77] [Article Influence: 81.0] [Reference Citation Analysis]
11 Goette A, Merino JL, De Caterina R, Huber K, Heidbuchel H, Jin J, Lip GYH. Effect of concomitant antiplatelet agents on clinical outcomes in the edoxaban vs warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomized trial. Clin Res Cardiol 2020;109:1374-80. [PMID: 32236718 DOI: 10.1007/s00392-020-01635-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Mull HJ, Shin MH, Engle RL, Linsky AM, Kalver E, Lamkin R, Sullivan JL. Veterans Perceptions of Satisfaction and Convenience with Anticoagulants for Atrial Fibrillation: Warfarin versus Direct Oral Anticoagulants. Patient Prefer Adherence 2020;14:1911-22. [PMID: 33116435 DOI: 10.2147/PPA.S279621] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Lee CW, Liu ME, Lee TM, Chang RY, Huang CY, Hu YF, Yeh HI. Patient satisfaction with dabigatrean and warfarin for stroke prevention in atrial fibrillation: Taiwan PASSION study. J Chin Med Assoc 2021;84:375-82. [PMID: 33784265 DOI: 10.1097/JCMA.0000000000000496] [Reference Citation Analysis]
14 Brandes A, Crijns HJGM, Rienstra M, Kirchhof P, Grove EL, Pedersen KB, Van Gelder IC. Cardioversion of atrial fibrillation and atrial flutter revisited: current evidence and practical guidance for a common procedure. Europace 2020;22:1149-61. [PMID: 32337542 DOI: 10.1093/europace/euaa057] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 13.0] [Reference Citation Analysis]